Two people are dead and several others remain in hospital after a confirmed outbreak of meningitis B in Kent — a strain of the disease considered the most lethal form of bacterial meningitis and one that the majority of teenagers and young adults in Britain have never been vaccinated against.
Health officials have described the situation as “very concerning,” with emergency measures now being rolled out across the county. Here is what you need to know.
What is meningitis B?
Meningitis B is now the most common cause of bacterial meningitis in the UK, responsible for more than 80 per cent of all invasive cases. It attacks the protective membranes surrounding the brain and spinal cord and can cause life-threatening blood poisoning and severe brain inflammation — a condition collectively known as meningococcal disease.
What makes it especially dangerous is the speed at which it progresses. Professor Paul Hunter, an infectious diseases expert at the University of East Anglia, warned: “You can go from being relatively mild to on death’s door within a matter of a few hours.” MenB is also not a single strain but a collection of many variants, making it harder to control through vaccination.
Who has died in the Kent outbreak?
The two confirmed deaths are Juliette Kenny, an 18-year-old A-level student at Queen Elizabeth’s Grammar School in Faversham, and an unnamed University of Kent student. A third Kent grammar school has since confirmed a case, and several other patients continue to receive hospital treatment. The current outbreak has been linked to students sharing vapes on a night out.
Why are most teenagers unprotected?
The MenB vaccine was introduced in 2015 and is currently offered only to babies as part of the routine childhood immunisation schedule. Anyone born before 2015 — including the vast majority of current secondary school pupils and university students — has not received it unless their parents paid privately, at a cost of more than £100.
A separate meningitis vaccine is offered to children aged 13 or 14, but it covers only strains A, C, W and Y. It provides no protection against MenB.
Who is most at risk?
Babies under one year old face the highest risk due to their underdeveloped immune systems. However, teenagers and young adults are considered particularly vulnerable — not only to catching the disease but to spreading it. Around one in ten people in the general population carry the meningococcal bacteria harmlessly in the back of the throat without knowing it. Among university students, that figure rises to as many as one in three.
Transmission requires close contact — coughing, sneezing, kissing or sharing items such as drinks or vapes.
Beyond young people, several other groups face elevated risk. Those suffering from influenza are more susceptible because the virus weakens the immune system and damages the airways, allowing bacteria to take hold. Smokers, frequent visitors to bars and clubs, people with conditions such as cancer, diabetes, kidney or liver disease, and those living with HIV all face significantly higher odds of serious infection. People without a functioning spleen — around 12,000 in the UK — are also at elevated risk, as the spleen plays a key role in defending against certain bacteria.
What are the symptoms to watch for?
Early symptoms are easily mistaken for a common viral illness, which is why doctors urge families not to wait for the signs they might consider classic. The illness typically begins with a sudden high fever, severe headache, nausea, muscle pain and general malaise. In young people, sensitivity to light, confusion and unusual drowsiness are also warning signs. In babies, signs can include refusing feeds, unusual irritability and a weak or high-pitched cry.
A rash that does not fade when pressed is a well-known indicator of meningococcal disease — but experts warn it often appears late, and in some cases not at all. Early medical attention is critical.
Why isn’t there a routine teen vaccine?
The absence of a routine MenB booster for teenagers is not accidental. Last year, the Joint Committee on Vaccination and Immunisation concluded it was not cost-effective to extend the programme to adolescents, citing the vaccine’s more limited and shorter-lived protection compared to those covering other strains, and the fact that it does not significantly reduce transmission of the bacteria in the wider population.
Uptake of existing vaccines is also a concern. Just 66.5 per cent of Year 9 pupils in the North West received the MenACWY jab in the 2024-25 academic year.
What are officials doing now — and could more have been done sooner?
Health officials must first determine whether the specific Kent strain is covered by existing MenB vaccines — a question the UKHSA is working to answer urgently. Professor Andrew Pollard, director of the Oxford Vaccine Group, said that even if there is a match, vaccine protection takes time to develop, meaning the immediate priority is ensuring that anyone exposed receives antibiotics as quickly as possible.
Questions have been raised about whether the public response came swiftly enough. One public health source told the BBC that preventative antibiotics and wider alerts should perhaps have been issued sooner. The UKHSA has disputed this, insisting local teams “acted very, very quickly.” Professor Hunter said that in his experience, going public at the point local GPs were informed of a problem was standard practice and could be critical: “If doctors know that there is a problem with meningococcal disease in the area, then they’re more likely to take those early symptoms seriously.”
What happens next?
Meningitis charities including Meningitis Now are calling for an adolescent booster programme to be in place by 2030. Conservative MP Helen Whately, whose constituency includes Faversham, has urged ministers to consider a catch-up vaccination campaign. Whether the current outbreak prompts a formal review of immunisation policy for teenagers is likely to become a key question for the Government in the weeks ahead.
